- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05247424
Pretreatment With Unfractionated Heparin for ST Elevation Myocardial Infarction (UFH-STEMI)
Rupture of a coronary artery plaque leads to thrombotic occlusion of the coronary artery and would present as ST segment elevation myocardial infarction. Early treatment with aspirin and early primary percutaneous coronary intervention are indicated. Anticoagulation therapy, usually with unfractionated heparin, is required during percutaneous coronary intervention.
Investigators hypothesis is that pretreatment with unfractionated heparin in addition to aspirin at first medical contact may facilitate spontaneous reperfusion of culprit artery and procedural thrombotic complication in patients with ST elevation myocardial infarction without significant risk of bleeding complications.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomization of patients with STEMI at first medical contact in a 1:1 ratio into an intervention group receiving 100 IU of unfractionated heparin (UFH) per kilogram of body weight IV and later additionally UFH after diagnostic coronary angiography according to the activated clotting time (ACT) and a control group receiving only UFH after diagnostic coronary angiography at the dose of 100 IU per kilogram of body weight.
The primary end point of the study is TIMI flow at coronary angiography. Secondary endpoints are: Bleeding complications (defined by BARC score), occurrence of cardiogenic shock, and 30-day mortality.
Investigators plan to randomize 600 patients.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Miša Fister, MD, PhD
- Phone Number: +38615229825
- Email: misa.fister@gmail.com
Study Contact Backup
- Name: Tomaz Goslar, MD, PhD
- Phone Number: +38615229825
- Email: tomaz.goslar@gmail.com
Study Locations
-
-
-
Ljubljana, Slovenia, 1000
- Recruiting
- UMC Ljubljana
-
Contact:
- Tomaž Goslar, MD
- Phone Number: +38615229532
- Email: tomaz.goslar@ukclj.si
-
Contact:
- Misa Fister, MD
- Phone Number: +38615229599
- Email: misa.fister@kclj.si
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patients with STEMI referred for primary PCI
- Duration of symptoms less than 6 hours before presentation
Exclusion Criteria:
- Pregnancy
- Cardiogenic shock at presentation (hemodynamic instability)
- Cardiac arrest before randomization
- Duration of symptoms for more than 6 hours before presentation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early unfractionated heparin
Administration of UFH at a dose of 100 IU/kg body weight at first medical contact.
Addition of UFH before coronary intervention according to ACT measurement after coronary angiography before coronary intervention.
|
Unfractionated heparin at dose of 100 IU /kg body weight
|
No Intervention: Control - Unfractionated heparin for coronary intervention only
Control arm with administration of UFH at a dose of 100 IU/kg body weight after coronary angiography before coronary intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TIMI flow
Time Frame: Day 0
|
TIMI flow in culprit coronary artery at first coronary angiography
|
Day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bleeding
Time Frame: Day 0
|
Bleeding assessed by Bleeding Academic Research Consortium (BARC) score.
BARC incorporates 5 bleeding types, ranging from BARC 0 - no bleeding to BARC 5 - fatal bleeding.
|
Day 0
|
Cardiogenic shock
Time Frame: Day 0 to 10
|
Presence of cardiogenic shock at any time after randomization
|
Day 0 to 10
|
30 day mortality after STEMI
Time Frame: 30 days
|
30-day mortality after STEMI
|
30 days
|
Troponin I concentration 24 h after primary PCI
Time Frame: 24 h
|
Troponin I concentration 24 h after primary PCI
|
24 h
|
Collaborators and Investigators
Investigators
- Study Chair: Miša Fister, MD, PhD, UMC Ljubljana
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- ST Elevation Myocardial Infarction
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Anticoagulants
- Heparin
- Calcium heparin
Other Study ID Numbers
- Heparin-STEMI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on STEMI - ST Elevation Myocardial Infarction
-
Stony Brook UniversityHennepin County Medical Center, MinneapolisUnknownAcute Coronary Syndrome | STEMI | NSTEMI - Non-ST Segment Elevation MI | Non ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Coronary Artery Thrombosis (Diagnosis) | Non ST Segment Elevation Acute Coronary Syndrome and other conditionsUnited States
-
Assiut UniversityNot yet recruitingST-segment Elevation Myocardial Infarction (STEMI)
-
Assiut UniversityUnknownST-segment Elevation Myocardial Infarction (STEMI)
-
Hellenic Cardiovascular Research SocietyCompletedMyocardial Infarction | ST Segment Elevation Myocardial Infarction (STEMI)Greece
-
University College, LondonCompletedST-segment Elevation Myocardial Infarction (STEMI)Mauritius
-
A.H. TavenierIsalaCompletedSTEMI | STEMI - ST Elevation Myocardial InfarctionNetherlands
-
RenJi HospitalNot yet recruitingST-segment Elevation Myocardial Infarction (STEMI)
-
Peking University Third HospitalNot yet recruitingST-segment Elevation Myocardial Infarction (STEMI)
-
The First Affiliated Hospital with Nanjing Medical...Completed
-
Samsung Medical CenterRainMed Medical; Shanghai Institute of Cardiovascular DiseasesActive, not recruitingST-segment Elevation Myocardial Infarction (STEMI)United States, China
Clinical Trials on Unfractionated heparin
-
Robert F. JamesIndiana University School of MedicineSuspendedNeurobehavioral Manifestations | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, Intracranial | Intracranial Aneurysm | Heparin-induced Thrombocytopenia Type IIUnited States
-
Vanderbilt UniversityTerminatedHeart Failure | Acute Kidney Injury | Acute Renal FailureUnited States
-
Christine RibicMcMaster University; LEO PharmaCompleted
-
University of PatrasCompletedCoronary AngiographyGreece
-
University of California, Los AngelesCompletedPregnancy Related | Antepartum DVTUnited States
-
Beijing Chao Yang HospitalCompletedVascular Diseases | Thrombosis | Thromboembolism | Pulmonary EmbolismChina
-
University Hospital, AntwerpUnknownHemodialysis | Acute Kidney InjuryBelgium
-
Kristian KarstoftActive, not recruitingBlood Coagulation DisorderDenmark
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Dutch Burns FoundationTerminatedBurn Injury | Inhalation InjuryNetherlands, Australia, Belgium
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia